Deflazacort | CAS#14484-47-0 | glucocorticoid

MedKoo Cat#: 315341 | Name: Deflazacort

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant. It is sold in the United Kingdom by Shire under the trade name Calcort. in Brazil as Cortax, Decortil, and Deflanil, and in Honduras as Flezacor. It is not available in the United States. Deflazacort is a prodrug. Its potency is around 70Â–90% that of prednisone.

Chemical Structure

Deflazacort

CAS#14484-47-0

Theoretical Analysis

MedKoo Cat#: 315341

Name: Deflazacort

CAS#: 14484-47-0

Chemical Formula: C25H31NO6

Exact Mass: 441.2151

Molecular Weight: 441.52

Elemental Analysis: C, 68.01; H, 7.08; N, 3.17; O, 21.74

Price and Availability

Size	Price	Availability	Quantity
50mg	USD 350.00	2 Weeks
100mg	USD 550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Azacort; Calcort; Deflan; Cortax; DL-458-IT; DL 458-IT; DL458-IT; Emflaza; Enzocort; Flantadin; L-5458; L5458; L 5458; Lantadin; MDL 458; MDL-458; MDL458; Oxazacort;

IUPAC/Chemical Name

2-((6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-6a,8a,10-trimethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d]oxazol-8b-yl)-2-oxoethyl acetate

InChi Key

FBHSPRKOSMHSIF-GRMWVWQJSA-N

InChi Code

InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1

SMILES Code

CC(OCC([C@@]12N=C(C)O[C@]1([H])C[C@@]3([H])[C@@](CCC4=CC(C=C[C@@]45C)=O)([H])[C@]5([H])[C@@H](O)C[C@@]32C)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO.

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Deflazacort, a glucocorticoid, is an inactive prodrug and is converted rapidly to the active metabolite 21-desacetyldeflazacort. Deflazacort is used as an anti-inflammatory and immunosuppressant.

In vitro activity:

Therefore, the present study was undertaken to test effects of deflazacort on osteoclast-like cell formation in mouse bone marrow cultures and on the regulation of osteoprotegerin (OPG) and its ligand (RANKL) mRNA expressions by RT-PCR in the ST2 marrow stromal cells. TRAP-positive mononuclear cells increased after the treatment of deflazacort at 10(-9) to 10(-7) M alone for 6 days in a dose-dependent manner. Number of TRAP-positive multi-nucleated cells (MNCs) increased significantly with combined treatment of deflazacort at 10(-7) M and 1,25-(OH)2D3 at 10(-9) M compared to that of cultures treated with 1,25-(OH)2D3 alone (p<0.05). Exposure to deflazacort at 10(-7) M in the presence of 1,25-(OH)2D3 at 10(-9) M in the last 3-day culture had greater stimulatory effect on osteoclast-like cell formation than that of the first 3-day culture did. Deflazacort at 10(-10) -10(-6) M downregulated OPG and upregulated RANKL in mRNA levels in a dose-dependent manner. These observations suggest that deflazacort stimulate osteoclast precursor in the absence of 1,25-(OH)2D3 and enhance differentiation of osteoclasts in the presence of 1,25-(OH)2D3. Reference: J Korean Med Sci. 2001 Dec;16(6):769-73. https://pubmed.ncbi.nlm.nih.gov/11748360/

In vivo activity:

The hypothesis that deflazacort improves muscle function and promotes repair by increasing myogenic cell proliferation and fiber differentiation was tested. Mdx mice (3.5 weeks old) were treated with deflazacort (1.2 mg/kg) or vehicle for 4 weeks. Peak grip strength increased 15% within 10 days of treatment, and was maintained up to 6 weeks after the end of treatment in a second experiment. Expression of CK MM in the regenerating TA rose from 46% to 55% of total CK activity after deflazacort treatment. Satellite cells were more numerous and appeared earlier on new fibers, in concert with a threefold increase in proliferation by myogenin+ (but not MyoD+) myoblasts. Alpha2-Laminin mRNA expression and protein increased 1.3-5.5-fold relative to MM CK in regenerating and dystrophic TA, respectively. These studies support the hypothesis that deflazacort promotes functional gains, myogenic differentiation, myoblast fusion, and laminin expression in regenerating dystrophic muscle. Reference: Cell Transplant. Jul-Aug 2000;9(4):551-64. https://pubmed.ncbi.nlm.nih.gov/11038071/

	Solvent	mg/mL	mM
Solubility
	DMSO	73.0	165.34
	Ethanol	7.0	15.85

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 441.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Langhoff E, Olgaard K. In vitro immunosuppressive potency of deflazacort, a new bone-sparing corticosteroid on T lymphocytes, NK and K cells. Br J Clin Pharmacol. 1986 Feb;21(2):125-9. doi: 10.1111/j.1365-2125.1986.tb05165.x. PMID: 3485440; PMCID: PMC1400905. 2. Chung H, Kang YS, Hwang CS, Moon IK, Yim CH, Choi KH, Han KO, Jang HC, Yoon HK, Han IK. Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. J Korean Med Sci. 2001 Dec;16(6):769-73. doi: 10.3346/jkms.2001.16.6.769. PMID: 11748360; PMCID: PMC3054787. 3. Anderson JE, Weber M, Vargas C. Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy. Cell Transplant. 2000 Jul-Aug;9(4):551-64. doi: 10.1177/096368970000900411. PMID: 11038071. 4. Dubinin MV, Talanov EY, Tenkov KS, Starinets VS, Belosludtseva NV, Belosludtsev KN. The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy. Int J Mol Sci. 2020 Nov 19;21(22):8763. doi: 10.3390/ijms21228763. PMID: 33228255; PMCID: PMC7699511.

In vitro protocol:

In vivo protocol:

1. Anderson JE, Weber M, Vargas C. Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy. Cell Transplant. 2000 Jul-Aug;9(4):551-64. doi: 10.1177/096368970000900411. PMID: 11038071. 2. Dubinin MV, Talanov EY, Tenkov KS, Starinets VS, Belosludtseva NV, Belosludtsev KN. The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy. Int J Mol Sci. 2020 Nov 19;21(22):8763. doi: 10.3390/ijms21228763. PMID: 33228255; PMCID: PMC7699511.

1: McDonald CM, Sajeev G, Yao Z, McDonnell E, Elfring G, Souza M, Peltz SW, Darras BT, Shieh PB, Cox DA, Landry J, Signorovitch J; ACT DMD Study Group and the Tadalafil DMD Study Group. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve. 2019 Oct 10. doi: 10.1002/mus.26736. [Epub ahead of print] PubMed PMID: 31599456. 2: Kucukpolat S, Kocaaslan R, Kadihasanoglu M, Bagcioglu M, Kocan H, Sarica K. Is Medical Therapy for Distal Ureteral Stones Efficient? Tamsulosin versus Deflazacort: A Prospective Randomised Trial. Aktuelle Urol. 2019 Sep 19. doi: 10.1055/a-0770-2627. [Epub ahead of print] PubMed PMID: 31537025. 3: Tantawy MA, Alweshahy S, Elshabasy DA, Youssef NF. Simultaneous Determination of Co-administrated Deflazacort, Aprepitant and Granisetron in Dosage Forms and Spiked Human Plasma by RP-HPLC/PAD. J Chromatogr Sci. 2019 Aug 28. pii: bmz062. doi: 10.1093/chromsci/bmz062. [Epub ahead of print] PubMed PMID: 31504281. 4: Yun BH, Joo DJ, Seo SK, Cho SH, Choi YS, Lee BS. Effect of deflazacort on pregnancy outcome in kidney transplant patients: should we change the immunosuppressant before conception? BMC Nephrol. 2019 May 14;20(1):161. doi: 10.1186/s12882-019-1346-6. PubMed PMID: 31088388; PubMed Central PMCID: PMC6515635. 5: Fappi A, Neves JC, Sanches LN, Massaroto E Silva PV, Sikusawa GY, Brandão TPC, Chadi G, Zanoteli E. Skeletal Muscle Response to Deflazacort, Dexamethasone and Methylprednisolone. Cells. 2019 May 1;8(5). pii: E406. doi: 10.3390/cells8050406. PubMed PMID: 31052442; PubMed Central PMCID: PMC6562646. 6: Trujillo-Trujillo MJ, González-Mancebo E, Gandolfo-Cano M, Mohedano-Vicente E, Martínez-Morán C. Deflazacort-Induced Erythema Multiforme Exudativum Successfully Treated With a Single Dose of Etanercept. J Investig Allergol Clin Immunol. 2018 Oct;28(5):338-339. doi: 10.18176/jiaci.0277. PubMed PMID: 30350788. 7: Sardana K, Bajaj S, Bose SK. Successful treatment of PAPA syndrome with minocycline, dapsone, deflazacort and methotrexate: a cost-effective therapy with a 2-year follow-up. Clin Exp Dermatol. 2019 Jul;44(5):577-579. doi: 10.1111/ced.13792. Epub 2018 Sep 26. PubMed PMID: 30259545. 8: Shieh PB, Mcintosh J, Jin F, Souza M, Elfring G, Narayanan S, Trifillis P, Peltz SW, Mcdonald CM, Darras BT; THE ACT DMD STUDY GROUP. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial. Muscle Nerve. 2018 Nov;58(5):639-645. doi: 10.1002/mus.26191. Epub 2018 Sep 27. PubMed PMID: 30028519; PubMed Central PMCID: PMC6767037. 9: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500900/ PubMed PMID: 29999959. 10: Hussar DA, Bailey KJ. Semaglutide, Ertugliflozin, and Deflazacort. J Am Pharm Assoc (2003). 2018 May - Jun;58(3):321-325. doi: 10.1016/j.japh.2018.04.005. PubMed PMID: 29739505. 11: Bashir MSM, Saleem M, Choudhari U. Deflazacort-induced Acneiform Eruptions. J Pharm Bioallied Sci. 2017 Oct-Dec;9(4):284-286. doi: 10.4103/jpbs.JPBS_67_17. PubMed PMID: 29456382; PubMed Central PMCID: PMC5810081. 12: Ganapati A, Ravindran R, David T, Yadav B, Jeyaseelan V, Jeyaseelan L, Danda D. Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study. Lupus. 2018 Jan 1:961203317751854. doi: 10.1177/0961203317751854. [Epub ahead of print] PubMed PMID: 29320974. 13: de Carvalho SC, Matsumura CY, Santo Neto H, Marques MJ. Identification of plasma interleukins as biomarkers for deflazacort and omega-3 based Duchenne muscular dystrophy therapy. Cytokine. 2018 Feb;102:55-61. doi: 10.1016/j.cyto.2017.12.006. Epub 2017 Dec 22. PubMed PMID: 29276972. 14: Chrzanowski SM, Poudyal R. Deflazacort-New Costs of an Old Medicine. JAMA Neurol. 2018 Feb 1;75(2):143-144. doi: 10.1001/jamaneurol.2017.3704. PubMed PMID: 29228076. 15: Deflazacort (Emflaza) for Duchenne muscular dystrophy. Med Lett Drugs Ther. 2017 Sep 11;59(1529):153-154. PubMed PMID: 28880848. 16: Pereira JA, Mauricio AF, Marques MJ, Neto HS. Dual Therapy Deflazacort/Doxycyclyne Is Better Than Deflazacort Monotherapy to Alleviate Cardiomyopathy in Dystrophin-Deficient mdx Mice. J Cardiovasc Pharmacol Ther. 2017 Sep;22(5):458-466. doi: 10.1177/1074248416686189. Epub 2016 Dec 28. PubMed PMID: 28793824. 17: Gupta N, Ganpati A, Mandal S, Mathew J, Goel R, Mathew AJ, Nair A, Ramasamy P, Danda D. Mycophenolate mofetil and deflazacort combination in neuropsychiatric lupus: a decade of experience from a tertiary care teaching hospital in southern India. Clin Rheumatol. 2017 Oct;36(10):2273-2279. doi: 10.1007/s10067-017-3775-6. Epub 2017 Aug 7. PubMed PMID: 28785855. 18: Escudero AI, Marín P, Cárceles CM, Escudero E. Pharmacokinetics of deflazacort in rabbits after intravenous and oral administration and its interaction with erythromycin. J Vet Pharmacol Ther. 2018 Feb;41(1):e10-e15. doi: 10.1111/jvp.12442. Epub 2017 Jul 25. PubMed PMID: 28741668. 19: Jensen L, Petersson SJ, Illum NO, Laugaard-Jacobsen HC, Thelle T, Jørgensen LH, Schrøder HD. Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy. J Musculoskelet Neuronal Interact. 2017 Jun 1;17(2):8-18. PubMed PMID: 28574407; PubMed Central PMCID: PMC5492315. 20: Deshmukh R, Sharma L, Tekade M, Kesharwani P, Trivedi P, Tekade RK. Force degradation behavior of glucocorticoid deflazacort by UPLC: isolation, identification and characterization of degradant by FTIR, NMR and mass analysis. J Biomed Res. 2016 Mar;30(2):149-161. doi: 10.7555/JBR.30.20150074. Epub 2016 Feb 20. PubMed PMID: 28276670; PubMed Central PMCID: PMC4820892.